This manuscript describes a series of assays for measuring the effects of multiple preparations of Abeta oligomers in vitro, and the use of those assays to find small molecule antagonists of Abeta oligomers that are capable of reversing cognitive defects in mouse models of Alzheimer's disease. The gene discussed is APP; the disease is early-onset autosomal dominant Alzheimer disease.